HESKA CORPORATION INVESTOR PRESENTATION

HSKA

SEPTEMBER 23, 2020

SIDOTI & CO. FALL CONFERENCE 2020

01 SAFE HARBOR NOTICESThis presentation contains forward-looking information related to the Heska Corporation (the “Company”). This forward-looking information generally includes statements that

are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “expects,” “intends,” “strategy,”

“future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. All of the statements in this document, other than historical facts, are forward-looking

statements and are based on a number of assumptions that could ultimately prove inaccurate and cause actual results to materially deviate from forward-looking statements.

Forward-looking statements in this document include, among other things, statements with respect to future sales, sales split percentages, sales geography percentages,

market share, and strategic goals, the expected timing of the scil Acquisition and its funding and its anticipated benefits; the expected conversion of the Preferred Shares into

shares of Public Common Stock; anticipated investments and growth; and the number of customers that the Company will be able to acquire and retain. Such statements are

subject to risks and uncertainties, including, but not limited to, uncertainties related to the closing of the Acquisition; the obtaining of shareholder approval to increase the

number of shares of Public Common Stock authorized by the Company’s Certificate of Incorporation; the ability to achieve the anticipated benefits of the Acquisition

uncertainties related to supplier availability, competing suppliers, any product’s ability to perform and be recognized as anticipated, in particular when such product is under

development; uncertainties related to Heska’s ability to sell and market its products in an economically sustainable fashion, including related to varying customs, cultures,

languages and sales cycles and uncertainties with foreign political and economic climates; and the Company’s ability to integrate the acquired scil business within its existing

operations; and new product development and release schedules. Other factors that could cause actual results to differ materially from those matters expressed in or implied

by such forward-looking statements are set forth under “Risk Factors” in the Company’s most recent annual report on Form 10-K and subsequent quarterly reports on Form

10-Q.

2

1. Pet Healthcare Universe and Heska Overview

2. Heska Three Point Strategy

- Double Customers & Geography Served

- Double Product & Revenue Streams Served

- Continue Core Base Business Growth

(~12% Consumables Target)

Today’s Presentation

Pet Healthcare Universe Overview

Diagnostics Drives “Test & Treat”Diagnostics Drives >25% of Care

Diagnostics Drives Rx & Therapy

(1) Point of Care (2) Reference Lab(3) Rapid Singles (4) Imaging

5

Supportive Growth Trends Global & Demographic

2.6 2.6 2.6

3.3

Silent Generation Baby Boomers Gen X Millennials

Average Canine Vet Visits per Year by Owner AgeAverage Canine Vet Visits per Year by Owner AgeAverage Canine Vet Visits per Year by Owner AgeAverage Canine Vet Visits per Year by Owner Age

1,813 1,976

2,154

2,352

2,574

2017 2018 2019 2020 2021

Global Veterinary Diagnostics Market > $2 BillionGlobal Veterinary Diagnostics Market > $2 BillionGlobal Veterinary Diagnostics Market > $2 BillionGlobal Veterinary Diagnostics Market > $2 Billion

~26,000 veterinary hospitals (USA) ~65,000 veterinary hospitals (Intl)

Amounts estimated. Source: American Pet Prod Assoc Generational Report; 2017-18 Pet Owners’ Survey; American Pet Products Association; Technavio Global Veterinary Diagnostics Market 2017-2021 report

Point of Care Reference Laboratory

DIAGNOSTICS IS CENTRAL & SCARCE

≈ 2%

≈ 48%

≈ 50%

North America Reference Lab Share

≈ 23%

≈ 12%

≈ 65%

North America POC Share

Information derived from publicly available information data disclosed by third-party sources, our own internal estimates based on such data, and our knowledge of the industry; it has not been independently verified and we cannot assure you of its accuracy or completeness. Our internal estimates have not been independently verified. While we are not aware of any misstatements regarding this information, we cannot guarantee its accuracy or completeness.

Veterinary Healthcare

• Humanization of pets globally

• Adoption rates at historic levels

• Lifecycle “family member” juvenile, wellness and aging care

• Greater awareness of pet health and pet symptoms

• Historically recession resistant

• Positive regulatory, payor and demographic trends

• Accelerating industry investment and consolidation

Point of Care Diagnostics

• ~ 6%-8% Annual Global Veterinary Diagnostics Growth1

• Major veterinarian revenue / profit center in 90% of hospitals

• Diagnostics utilization is key (15%-25%+ of hospital pet visits)1

• Increases in hospital pet visits (~2%-5%)1

• Prioritized and favored by veterinarians (veterinary licensure

required)

• New technologies and advancements pull tests to point of care

• Pricing tends to increase each year

• High priority spend item has revenue security in tight budgets

1. Information derived from publicly available information data disclosed by third-party sources, our own internal estimates based on such data, and our knowledge of the industry; it has not been independently verified and we cannot assure you of its accuracy or completeness. Our internal estimates have not been independently verified. While we are not aware of any misstatements regarding this information, we cannot guarantee its accuracy or completeness. Source: American Pet Prod Assoc Generational Report; 2017-18 Pet Owners’ Survey; American Pet Products Association; Technavio Global Veterinary Diagnostics Market 2017-2021 report.

Heartworm

Therapeutic

Heartworm

Diagnostic

Element DC

Chemistry

Vet/IV

Infusion Pump

Element DC5X

Chemistry

Element RC

Chemistry

Element HT5

Hematology

Element i+

Immunoassay

Element POC

Gas & E-M Lyte

Element COAG

Coagulation

Element UF

Urine & Fecal

Cloud Data

Solution

Hospital Digital

Radiography

Portable Digital

Radiography

Digital

Ultrasound

Allergy Diagnostic

Immunotherapy9

Leading Point of Care Full Product Portfolio “Complete Voice of the Pet”

Digital

Endoscopy

~90% of Heska POC Lab Consumables on Long-Term Subscription (1), (2), (3)

1. Includes Corporate Accounts estimates similar to individual accounts CSV (“Contract Subscription Value”). 2. As of December 31, 2019.

3. Represents minimum contract subscription value / subscription months

Subscriber Retention >95%

Minimum contract subscription value ($MM)3

+34%+34%+34%+34%+11%+11%+11%+11%

+28%+28%+28%+28%

02

2015201520152015 2016201620162016 2017201720172017 2018201820182018 2019201920192019

Subscriptions 1,239 1,667 1,950 2,175 2,376

% Growth N/A 35% 17% 12% 9%

Months Under Subscription 54,200 68,750 75,950 90,850 100,249

% Growth N/A 27% 10% 20% 10%

Monthly Contract Subscription Value $701 $742 $743 $792 $864

% Growth N/A 13% 0% 7% 9%

+41%+41%+41%+41%

$38.0

$51.0$56.4

$72.0

$101.6

- Double Customers & Geography Served

- Double Product & Revenue Streams Served

- Continue Core Base Business Growth

(~12% Consumables Target)

Heska Three Point Strategy for 2018 to 2023

Expect $175 - $185 Million in Sales for 2020 (consolidated)

Over 500 Professionals with over 150 Direct Sales

Direct Sales Teams in 10 Countries

Logistics and Operations in 7 Countries

Installations of over 30,000 Analyzers

Information from Heska data and internal estimates of scil data provided to Heska from scil. Direct Sales teams include RM, TM, ISAM, FSR, Imaging, Sales Management, and Other. Heska has not independently verified the data from third party and cannot assure its accuracy or completeness,and Heska internal and scil estimates have not been independently verified. Sales estimate based on scil closing date on or before April 1, 2020, adjustments anticipated for equipment portion of revenue recognition under subscriptions agreements, integration effects, and other variabilities;estimate may materially deviate from actual performance. While Heska is not aware of any misstatements regarding this information, Heska cannot guarantee its accuracy or completeness. Information regarding future sales are forward-looking statements and actual results can materially differfrom those noted, due to several factors, including but not limited to market, currency, integration, supplier, distributor, scil, and Heska performance and those mentioned in Safe Harbor and forward-looking statements disclaimer herein.

Double Customers and Geography

Now we Serve 25 Markets… and Growing.

United States

Canada

Australia

Latin America

Germany Spain

Canada France

Italy Netherlands

Czech Republic Poland

United Kingdom and More

Spain France

Information regarding market share and market position is derived from data from publicly available information disclosed by third party sources and Heska internal estimates based on such data, scil data, and Heska’s knowledge of the industry. Heska has not independently verified the data fromthird party sources and cannot assure its accuracy or completeness, and Heska internal and scil estimates have not been independently verified. Data specifically excludes items not point of care, including central reference laboratories and single use “rapid” tests. While Heska is not aware of anymisstatements regarding this information, Heska cannot guarantee its accuracy or completeness. Information regarding future sales, sales split percentages, sales geography percentages, and goals are forward-looking statements and actual results can materially differ from those noted, due toseveral factors, including but not limited to market, currency, integration, supplier, distributor, scil, and Heska performance and those mentioned in Safe Harbor and forward-looking statements disclaimer herein.

Now we are #1, #2, or #3 Key Markets… and Growing.

United States #3 ≈ 12.5%

Canada #3 ≈ 13.0%

Germany #1 ≈ 40.0%

Spain #1 ≈ 40.0%

France #2 ≈ 30.0%

Information regarding market share and market position is derived from data from publicly available information disclosed by third party sources and Heska internal estimates based on such data, scil data, and Heska’s knowledge of the industry. Heska has not independently verified the data fromthird party sources and cannot assure its accuracy or completeness, and Heska internal and scil estimates have not been independently verified. Data specifically excludes items not point of care, including central reference laboratories and single use “rapid” tests. While Heska is not aware of anymisstatements regarding this information, Heska cannot guarantee its accuracy or completeness. Information regarding future sales, sales split percentages, sales geography percentages, and goals are forward-looking statements and actual results can materially differ from those noted, due toseveral factors, including but not limited to market, currency, integration, supplier, distributor, scil, and Heska performance and those mentioned in Safe Harbor and forward-looking statements disclaimer herein.

New Global Presence to Double Customer Opportunities

2018 Sales Geography(2)

North America

~60%-65%

Europe~30%

RoW ~3%

Canada

~7%

RoW 2%Canada 2%

Europe 5%

USA91%

2020 Sales Geography(1)

1. 2020 is forward-looking estimate subject to numerous factors outlined in the Company’s Second Quarter Financial Results press release of August 4, 2020 and Safe Harbor in this presentation. Amounts not GAAP and are estimates; results may materially differ. Management believes this visual will assist investors to understand the Company’s business and strategy.

2. All amounts rounded and not GAAP. Refer to 10K ending December 31, 2018 for GAAP, segments, revenue recognition, and other information relevant to (1) and (2).

~26,000 hospitals (USA) ~65,000 hospitals (Intl)

Estimated Consolidated Sales Mix

2018 Sales Mix (2)

15%POC Lab

45%

POC Imaging18%

Other Vaccine & Pharma

Other Core Comp. Animal

22%

2020 Sales Mix(1)

~8%

POC Lab~60%

POC Imaging~20%

~12%

Other Vaccine & Pharma

Other Core Comp. Animal

1. 2020 is forward-looking estimate subject to numerous factors outlined in the Company’s Second Quarter 2020 Financial Results press release of August 4, 2020 and Safe Harbor in this presentation. Amounts not GAAP and are estimates; results may materially differ.

2. All amounts rounded and not GAAP. Refer to 10K ending December 31, 2018 for GAAP, segments, revenue recognition, and other information relevant to (1) and (2).

Heska is a Good Owner of These Assets with Strong Management in First Five Year Plan (2013-2017)

1. 2017 U.S Tax Reform impacts of +/- ($5.9M) included, as further discussed in our Form 10-K/A for the year ended December 31,2017. 2. 2020 Outlook referred to as “2020 Recast Outlook” in Company’s Second Quarter Financial Results press release is forward-looking estimate subject to numerous factors outlined in the Company’s Second Quarter Financial Results press release on August 4, 2020 and Safe Harbor of this presentation.

$MM, except p/shareHeskaHeskaHeskaHeska

2013201320132013

HeskaHeskaHeskaHeska

2017201720172017

HeskaHeskaHeskaHeska

2020 Outlook2020 Outlook2020 Outlook2020 Outlook2222

RevenueRevenueRevenueRevenue $78.3 $129.3 $175 - $185

Gross margin %Gross margin %Gross margin %Gross margin % 39% 45%

Operating margin %Operating margin %Operating margin %Operating margin % (2%) 14%

Operating IncomeOperating IncomeOperating IncomeOperating Income ($1.43) $18.2

EarningsEarningsEarningsEarnings per shareper shareper shareper share ($0.21) $1.3¹

Adjusted EBITDA MarginAdjusted EBITDA MarginAdjusted EBITDA MarginAdjusted EBITDA Margin 4% - 6%

AssetsAssetsAssetsAssets $93.6 $135.8

EquityEquityEquityEquity $47.1 $100.4

Getting Product

Right

Getting TeamRight

GettingCostsRight

Getting ModelRight

Getting

NarrativeRight

Double Products and Revenue Streams

Research and Growth Development Investments

2018 $19MM R&D Business Development Investments

• Core Technologies and Inventions for Product Pipeline

• Sales Team Expansion

• Prepare Heska to Manufacture Heska POC Diagnostics Test Cards

2019 Accelerated R&D up +190% YOY

• New Analyzer Platforms for 2nd Half 2019 & FY2020

International Markets 2020

Global Veterinary and Animal Health

20 Tests per Rotor (v 14 Tests on Launch)

Two way wireless and Ethernet

Superior run-time and performance

Under 12 pounds (5.5kg)

Superior Heska Reset Economics

2020 Major Product Expansion

Major Drivers

2020 Assays in DevelopmentNon-Regulatory (USDA)

Total T4

Cortisol Canine

TSH

Progesterone

2020 Assays in DevelopmentRegulated (USDA)

Canine Heartworm (4+ Plex)

Lyme (4+ Plex)

Anaplasma (4+ Plex)

Ehrlichia (4+ Plex)

High Sensitivity Immunodiagnostics Multi Plex Analyzer (>$100M Target)

2020 Major Product Expansion

Major Drivers

5 Million Urine Sedimentation Exams Annually

7,000+ Competitive Sediment Analyzers in validated market

2020 Major Product Expansion

Urine Automatic Imaging (>$100M Target)

30 Million Manual Point of Care Fecal Floatation Exams

Roundworm, Hookworm, Tapeworm, Whipworm, Flukeworm, Giardia & more…

(Mid 2021)

Fecal Automatic Imaging (>$300M Target)

Major Drivers

� Test Supplies and Test Beds Validated

� Alpha Instruments & Low Volume Test Supplies

� Sales Training & Public Marketing

(VMX Orlando, WVC Las Vegas)

Q4 2020 Beta Instruments & Test Supplies Manufacturing in Volume

Q2 2021 Production Instruments

Production and Development Plan Outlook

(Mid 2021)

2020 Major Product Expansion

Continue Core Business Growth

Continue Core Business Growth (Organic and Acquired)

1) Grow Market Share

• Continue New Single User Subscriptions Wins

• Continue Corporate Groups Sites Installs

• Continue Expanded Sales Teams

• Expand into International POC Market Share

3) Grow Price

• Price (4%) Annual Escalators in Subscriptions

• New Tests and Panels Launches

2) Grow Utilization in Existing Sites

• Launch New Tests on several Analyzers (2019-2021)

• Capture Positive Market Trends & Demographics

• More Patient Visits & Hospital Growth

• Higher % of Patient Visits doing a Diagnostic

4) Grow Products

• New and Upgrade Products from R&D

• New and Upgrade Products from Acquisitions

Q2 2020 Highlights

Key Metrics

• Revenue up 62.4% to $45.7MM

• Consolidated Gross Margin: 39.1%

• North America Gross Margin: 44.0%

• Adjusted EBITDA Margin: 9.1%

Commentary

• Record quarterly revenue benefited by growth in POC Lab Consumables and

recently completed scil acquisition

• Research, development, and commercial launch of key projects progressed in-line

with previously stated timelines

• CSV up 17% in period to record levels

• Subscriber retention strong and in-line with Company targets

• Reporting segments changed to reflect recent acquisitions and revenue profile

• Reaffirm 2020 Combined Outlook(1)(2) and other key targets

• Consolidated revenue ($175-$185 million), global POC Lab revenue ($105-$115

million), global POC Imaging revenue ($25-$35 million), former OVP segment revenue

($15-$16 million), Adjusted EBITDA Margin (4%-6%), and POC Lab Consumable growth

rate (~12%)

26

04

1. 2020 Combined Outlook is forward-looking estimate subject to numerous factors outlined in the Company’s First Quarter 2020 Financial Results press release on May 7, 2020 and Safe Harbor of this presentation. 2. 2020 Outlook referred to as “2020 Recast Outlook” in Company’s Second Quarter Financial Results press release is forward-looking estimate subject to numerous factors outlined in the Company’s Second Quarter Financial Results press release on August 4, 2020 and Safe Harbor of this presentation.